WST

West Pharmaceutical Services Inc
NYSEHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$23.93B
P/E Ratio
43.47
EPS
$7.82
Beta
1.14
52W High
$385.75
52W Low
$223.52
50-Day MA
$350.12
200-Day MA
$293.73
Dividend Yield
0.25%
Profit Margin
17.00%
Forward P/E
35.21
PEG Ratio
2.67

About West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$3.33B
Gross Profit (TTM)$1.22B
EBITDA$912.20M
Operating Margin22.50%
Return on Equity19.10%
Return on Assets11.40%
Revenue/Share (TTM)$46.30
Book Value$42.47
Price-to-Book8.07
Price-to-Sales (TTM)7.19
EV/Revenue7.21
EV/EBITDA27.28
Quarterly Earnings Growth (YoY)18.10%
Quarterly Revenue Growth (YoY)13.80%
Shares Outstanding$70.38M
Float$69.86M
% Insiders0.64%
% Institutions102.06%

Historical Volatility

HV 10-Day
18.26%
HV 20-Day
16.61%
HV 30-Day
16.96%
HV 60-Day
24.48%
HV Rank
0.0%

Volatility is currently expanding

Analyst Ratings

Consensus ($404.73 target)
3
Strong Buy
11
Buy
2
Hold

Latest News

West to Participate in Upcoming Investor Conferences

EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m.

PRNewsWire8/26/2026Neutral
West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.

Seeking Alpha7/24/2026Positive
West Pharmaceutical Services Q2 Earnings Call Highlights

West Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management's expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers.

MarketBeat7/24/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WST and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026